Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Tisotumab Vedotin: The First FDA-Approved Antibody-Drug Conjugate for Cervical Cancer

Author(s): Surya K. De*

Volume 22, Issue 16, 2022

Published on: 09 June, 2022

Page: [2808 - 2810] Pages: 3

DOI: 10.2174/1871520622666220421095240

conference banner
« Previous Next »
[1]
Canfell, K.; Kim, J.J.; Brisson, M.; Keane, A.; Simms, K.T.; Caruana, M.; Burger, E.A.; Martin, D.; Nguyen, D.T.N.; Bénard, É.; Sy, S.; Regan, C.; Drolet, M.; Gingras, G.; Laprise, J.F.; Torode, J.; Smith, M.A.; Fidarova, E.; Trapani, D.; Bray, F.; Ilbawi, A.; Broutet, N.; Hutubessy, R. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, 2020, 395(10224), 591-603.
[http://dx.doi.org/10.1016/S0140-6736(20)30157-4] [PMID: 32007142]
[2]
Muñoz, N.; Bosch, F.X.; de Sanjosé, S.; Herrero, R.; Castellsagué, X.; Shah, K.V.; Snijders, P.J.; Meijer, C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med., 2003, 348(6), 518-527.
[http://dx.doi.org/10.1056/NEJMoa021641] [PMID: 12571259]
[3]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN esti-mates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[4]
Snijders, P.J.; Steenbergen, R.D.; Heideman, D.A.; Meijer, C.J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol., 2006, 208(2), 152-164.
[http://dx.doi.org/10.1002/path.1866] [PMID: 16362994]
[5]
Brisson, M.; Kim, J.J.; Canfell, K.; Drolet, M.; Gingras, G.; Burger, E.A.; Martin, D.; Simms, K.T.; Bénard, É.; Boily, M.C.; Sy, S.; Regan, C.; Keane, A.; Caruana, M.; Nguyen, D.T.N.; Smith, M.A.; Laprise, J.F.; Jit, M.; Alary, M.; Bray, F.; Fidarova, E.; Elsheikh, F.; Bloem, P.J.N.; Broutet, N.; Hutubessy, R. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, 2020, 395(10224), 575-590.
[http://dx.doi.org/10.1016/S0140-6736(20)30068-4] [PMID: 32007141]
[6]
Tong, J.T.W.; Harris, P.W.R.; Brimble, M.A.; Kavianinia, I. An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules, 2021, 26(19), 5847.
[http://dx.doi.org/10.3390/molecules26195847] [PMID: 34641391]
[7]
Coleman, R.L.; Lorusso, D.; Gennigens, C.; González-Martín, A.; Randall, L.; Cibula, D.; Lund, B.; Woelber, L.; Pignata, S.; Forget, F.; Redondo, A.; Vindeløv, S.D.; Chen, M.; Harris, J.R.; Smith, M.; Nicacio, L.V.; Teng, M.S.L.; Laenen, A.; Rangwala, R.; Manso, L.; Mirza, M.; Monk, B.J.; Vergote, I.; Raspagliesi, F.; Melichar, B.; Gaba Garcia, L.; Jackson, A.; Henry, S.; Kral, Z.; Harter, P.; De Giorgi, U.; Bjurberg, M.; Gold, M.; O’Malley, D.; Honhon, B.; Vulsteke, C.; De Cuypere, E.; Denys, H.; Baurain, J-F.; Zamagni, C.; Tenney, M.; Gordinier, M.; Bradley, W.; Schlumbrecht, M.; Spirtos, N.; Concin, N.; Mahner, S.; Scambia, G.; Leath, C.; Farias-Eisner, R.; Cohen, J.; Muller, C.; Bhatia, S. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol., 2021, 22(5), 609-619.
[http://dx.doi.org/10.1016/S1470-2045(21)00056-5] [PMID: 33845034]
[8]
de Goeij, B.E.; Satijn, D.; Freitag, C.M.; Wubbolts, R.; Bleeker, W.K.; Khasanov, A.; Zhu, T.; Chen, G.; Miao, D.; van Berkel, P.H.; Parren, P.W. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol. Cancer Ther., 2015, 14(5), 1130-1140.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0798] [PMID: 25724665]
[9]
Joubert, N.; Beck, A.; Dumontet, C.; Denevault-Sabourin, C. Antibody-drug conjugates: The last decade. Pharmaceuticals (Basel), 2020, 13(9), 245.
[http://dx.doi.org/10.3390/ph13090245] [PMID: 32937862]
[10]
Coleman, R.L.; Lorusso, D.; Gennigens, C.; González-Martín, A.; Randall, L.; Cibula, D.; Lund, B.; Woelber, L.; Pignata, S.; Forget, F.; Redondo, A.; Vindeløv, S.D.; Chen, M.; Harris, J.R.; Smith, M.; Nicacio, L.V.; Teng, M.S.L.; Laenen, A.; Rangwala, R.; Manso, L.; Mirza, M.; Monk, B.J.; Vergote, I. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: a multi-centre, open-label, single-arm, phase 2 study. Lancet Oncol., 2021, 22(5), 609-619.
[http://dx.doi.org/10.1016/S1470-2045(21)00056-5] [PMID: 33845034]
[11]
Markham, A. Tisotumab vedotin: First approval. Drugs, 2021, 81(18), 2141-2147.
[http://dx.doi.org/10.1007/s40265-021-01633-8] [PMID: 34748188]
[12]
de Bono, J.S.; Concin, N.; Hong, D.S.; Thistlethwaite, F.C.; Machiels, J.P.; Arkenau, H.T.; Plummer, R.; Jones, R.H.; Nielsen, D.; Windfeld, K.; Ghatta, S.; Slomovitz, B.M.; Spicer, J.F.; Yachnin, J.; Ang, J.E.; Mau-Sørensen, P.M.; Forster, M.D.; Collins, D.; Dean, E.; Rangwala, R.A.; Lassen, U. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol., 2019, 20(3), 383-393.
[http://dx.doi.org/10.1016/S1470-2045(18)30859-3] [PMID: 30745090]
[13]
Hong, D.S.; Concin, N.; Vergote, I.; de Bono, J.S.; Slomovitz, B.M.; Drew, Y.; Arkenau, H.T.; Machiels, J.P.; Spicer, J.F.; Jones, R.; Forster, M.D.; Cornez, N.; Gennigens, C.; Johnson, M.L.; Thistlethwaite, F.C.; Rangwala, R.A.; Ghatta, S.; Windfeld, K.; Harris, J.R.; Lassen, U.N.; Coleman, R.L. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin. Cancer Res., 2020, 26(6), 1220-1228.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-2962] [PMID: 31796521]
[14]
Theunissen, J.W.; Cai, A.G.; Bhatti, M.M.; Cooper, A.B.; Avery, A.D.; Dorfman, R.; Guelman, S.; Levashova, Z.; Migone, T.S. Treating tissue factor-positive cancers with antibody-drug conjugates that do not affect blood clotting. Mol. Cancer Ther., 2018, 17(11), 2412-2426.
[http://dx.doi.org/10.1158/1535-7163.MCT-18-0471] [PMID: 30126944]
[15]
Breij, E.C.; de Goeij, B.E.; Verploegen, S.; Schuurhuis, D.H.; Amirkhosravi, A.; Francis, J.; Miller, V.B.; Houtkamp, M.; Bleeker, W.K.; Satijn, D.; Parren, P.W. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res., 2014, 74(4), 1214-1226.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-2440] [PMID: 24371232]
[16]
Clinical trial number NCT03438396 for "a trial of tisotumab vedotin in cervical cancer". ClinicalTrials.gov., 2014.
[17]
Clinical trial number NCT03245736 for "Tisotumab vedotin continued treatment in patients with solid tumors". ClinicalTrials.gov, 2014.
[18]
Fundamentals of Cancer Detection, Treatment, and Prevention, De, S. K; Wiley, 2022, p. 3527350659.
[19]
García-Alonso, S.; Ocaña, A.; Pandiella, A. Resistance to antibody-drug conjugates. Cancer Res., 2018, 78(9), 2159-2165.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-3671] [PMID: 29653942]
[20]
Khongorzul, P.; Ling, C.J.; Khan, F.U.; Ihsan, A.U.; Zhang, J. Antibody-drug conjugates: A comprehensive review. Mol. Cancer Res., 2020, 18(1), 3-19.
[http://dx.doi.org/10.1158/1541-7786.MCR-19-0582] [PMID: 31659006]

Rights & Permissions Print Cite
Article Metrics
26
6
© 2024 Bentham Science Publishers | Privacy Policy